New advances in the chronic lymphocytic leukaemia genome

New advances in the chronic lymphocytic leukaemia genome
Compared expression of some DE genes and pathways between C1/C2 is shown. Credit: (photo by Núria Lopez)

A study led by Dr. Roderic Guigó from the Centre for Genomic Regulation in Barcelona, as part of the Chronic Lymphatic Leukaemia Genome Consortium, has made new advances in the study of this disease. The work, which was published (in print version) last week in the journal Genome Research, scrutinised the functional profile of the genes and mutations associated with leukaemia.

The Spanish Chronic Lymphatic Leukaemia Genome Consortium had previously identified the principal mutations involved in the development of the disease. However, its functional profile, the activity of these mutated , had not been studied. Now, the researchers have sequenced the functional part of the of the leukaemia cells, the RNA, and several populations of healthy B lymphocytes from 98 patients.

The scientists found that there are thousands of genes that are expressed in a distinct way in leukaemia cells in comparison to the healthy B lymphocytes, and that their functions are also very different. In particular, in the leukaemia cells many genes are expressed relating to certain metabolic pathways that make them more active.

By observing these differences, the researchers have also clearly identified two subgroups of patients with different disease behaviour, making up one group of patients that do not need treatment for a long time, while others need it more quickly. In addition, they observed that the origin of these two subgroups could be found in the activating signals received by the leukaemia in the lymph nodes. "Thanks to the functional study of the genome we have been able to identify two clear subgroups amongst patients and we have confirmed that the aggressiveness of the disease is different in the two groups. Understanding the molecular basis of these two subgroups will enable specific treatments to be established for each of them", says Dr. Guigó.

add to favorites email to friend print save as pdf

Related Stories

Origin of chronic lymphatic leukaemia: lead discovered

Apr 11, 2012

Up until now the causes of the development of chronic lymphatic leukaemia, the most common form of cancer of the blood in Europe, have been unknown. At present a cure is not possible. A research group at the ...

Genome of one of the most aggressive lymphomas sequenced

Oct 22, 2013

Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new ...

Recommended for you

The fine line between breast cancer and normal tissues

5 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

6 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

Good bowel cleansing is key for high-quality colonoscopy

9 hours ago

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task ...

New rules for anticancer vaccines

10 hours ago

Scientists have found a way to find the proverbial needle in the cancer antigen haystack, according to a report published in The Journal of Experimental Medicine.

User comments